These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29710399)

  • 1. Patient-reported outcome assessment in acute leukemias: Moving beyond the barriers.
    Efficace F; Cottone F; Sparano F; Lo-Coco F
    Cancer; 2018 Jul; 124(14):3066-3067. PubMed ID: 29710399
    [No Abstract]   [Full Text] [Related]  

  • 2. ADCs Show Promise in Leukemias.
    Cancer Discov; 2016 Sep; 6(9):939. PubMed ID: 27388473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
    Kantarjian HM; Vandendries E; Advani AS
    N Engl J Med; 2016 Nov; 375(21):2100-2101. PubMed ID: 27959720
    [No Abstract]   [Full Text] [Related]  

  • 4. Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia.
    Mori J; Tsuda K; Tanimoto T
    N Engl J Med; 2016 Nov; 375(21):2100. PubMed ID: 27959721
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal antibodies in adult acute lymphoblastic leukemia.
    Kantarjian H
    Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises.
    Rizzari C
    Lancet Oncol; 2018 Feb; 19(2):159-160. PubMed ID: 29352702
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological Subtypes of Acute Lymphoblastic Leukemia- Beyond Morphology: Experience from Kidwai State Cancer Institute, Bengaluru, India.
    Rajkumar NN; Vijay RH
    J Assoc Physicians India; 2017 Jul; 65(7):14-17. PubMed ID: 28792162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of CD33 positive refractory acute lymphoblastic leukemia with Mylotarg.
    Cheung KC; Wong LG; Yeung YM
    Leuk Lymphoma; 2008 Mar; 49(3):596-7. PubMed ID: 18297542
    [No Abstract]   [Full Text] [Related]  

  • 9. CD22 monoclonal antibody therapies in relapsed/refractory acute lymphoblastic leukemia.
    Hoelzer D
    Cancer; 2013 Aug; 119(15):2671-4. PubMed ID: 23633448
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experiences of immunologic phenotyping in acute leukemia].
    Brinch L; Evensen SA; Stavem P; Smeland EB
    Tidsskr Nor Laegeforen; 1989 Feb; 109(4):443-6. PubMed ID: 2919374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Dahl J; Marx K; Jabbour E
    Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of peroxidase negative acute leukemias by monoclonal antibodies: III. Acute lymphoblastic leukemia.
    Imamura N; Kuramoto A
    J Clin Lab Anal; 1989; 3(2):88-94. PubMed ID: 2659759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inotuzumab: the most active single agent in acute lymphoblastic leukemia?
    Thomas DA
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):251-4. PubMed ID: 22706486
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytotoxicity of Campath-1H for acute lymphoblastic leukemia cells carrying the t(12;21) translocation.
    van der Velden VH
    Haematologica; 2006 Mar; 91(3):291A. PubMed ID: 16531248
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-CD22 therapy in acute lymphoblastic leukaemia.
    Hoelzer D
    Lancet Oncol; 2012 Apr; 13(4):329-31. PubMed ID: 22357139
    [No Abstract]   [Full Text] [Related]  

  • 16. Significance of lineage specific differentiation markers for complex classification of acute leukemias. II. Acute lymphoblastic leukemias.
    Lemez P
    Neoplasma; 1990; 37(3):267-81. PubMed ID: 2196472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of acute lymphocytic leukemias to the purine antagonist 6-mercaptopurine.
    LAW LW; TAORMINA V; BOYLE PJ
    Ann N Y Acad Sci; 1954 Dec; 60(2):244-50. PubMed ID: 14350530
    [No Abstract]   [Full Text] [Related]  

  • 18. The significance of phenotyping leukemias using monoclonal antibodies.
    Pombo-de-Oliveira MS; Tabak DG
    Braz J Med Biol Res; 1990; 23(9):763-72. PubMed ID: 2101315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of alemtuzumab in patients with CD52-positive acute leukemia.
    Tibes R; Keating MJ; Ferrajoli A; Wierda W; Ravandi F; Garcia-Manero G; O'Brien S; Cortes J; Verstovsek S; Browning ML; Faderl S
    Cancer; 2006 Jun; 106(12):2645-51. PubMed ID: 16688777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies: Immunoconjugates and autologous cellular therapy in acute lymphoblastic leukemia.
    Advani A
    Best Pract Res Clin Haematol; 2015; 28(2-3):116-23. PubMed ID: 26590768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.